Hoe Suk

The ER + breast cancer cell lines (MCF-7 and ZR75-1) were used in this study. MCF-7 cells (ATCC® HTB-22) were obtained from the American Type Culture Collection (Manassas, VA, USA) between 2012 and 2013. The ZR-75-1 cells (KCLB No. 21500) were obtained from the Korean Cell Line Bank (Seoul, Korea). MCF-7 cells were grown in DMEM (WelGENE, Seoul, Korea) supplemented with 10% fetal bovine serum (FBS) (WelGENE) and 1% penicillin-streptomycin (10,000 U/ml) (Gibco, Carlsbad, CA, USA).

MDA-MB-231 cells and RAW264.7 cells (Korean Cell Line Bank, Seoul, Korea) were cultured in RPMI-1640 (WelGENE, Seoul, Korea) and were grown in a 5% CO2 incubator at 37 °C. Lentiviral vectors encoding SerpinB2, including short hairpin RNA (shRNA) targeting SerpinB2 and scrambled shRNA, were purchased from Dharmacon (Lafayette, CO, USA). SerpinB2-overexpressing and -knockdown MDA-MB-231 cells were produced by the transduction of the SerpinB2 gene or shRNA using lentivirus [4].

BMC Cancer, Sep 2023 Heterogeneous tumor cells are thought to be a significant factor in the failure of endocrine therapy in estrogen receptor-positive (ER+) cancers. Culturing patient-derived breast cancer cells (PDBCCs) provides an invaluable tool in pre-clinical and translational research for the heterogeneity of cancer cells.